Immunohistochemical Study of Malignant Melanoma with HMB-45, Antibodies against S100 Protein, Melan-A, and Tyrosinase.
- Author:
Jae Hong PARK
1
;
Dong Youn LEE
;
Eil Soo LEE
Author Information
1. Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. eslee@smc.samsung.co.kr
- Publication Type:Original Article
- Keywords:
S100 protein;
HMB-45;
Melan-A;
tyrosinase
- MeSH:
Antibodies*;
Diagnosis;
MART-1 Antigen*;
Melanoma*;
Monophenol Monooxygenase*
- From:Korean Journal of Dermatology
2005;43(6):756-761
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Immunohistochemical confirmation is needed to correctly diagnose malignant melanoma, due to its heterogeneous histological appearance. OBJECTIVE: In the diagnosis of malignant melanoma, we evaluated the usefulness of recently introduced antibodies against Melan-A and tyrosinase, and compared them with antibodies against S100 protein and HMB-45. METHOD: Immunohistochemical staining with the above 4 antibodies was performed on 36 cases of malignant melanoma which had been excised. The percentage of positive tumor cells with the semi-quantitative estimation were than graded as follows; 0% = grade 0, 1-25% = grade 1, 26-50% = grade 2, 51-75% = grade 3, 76-100% = grade 4. We regarded grade 0 as negative, and grade 1 to 4 as positive. The association of Breslow thickness with the individual grade of 4 antibodies was then evaluated. RESULTS: 1. Positiveness of the 4 antibodies were as follows; 100% of the antibody against S100 protein, 97.2% of HMB-45, 97.2% of the antibody against tyrosinase, 91.7% of the antibody against Melan-A. 2. A case of a HMB-45 negative melanoma showed a grade 4 for the antibody against S100 protein, a grade 2 for the antibody against Melan-A, and a grade 3 for the antibody against tyrosinase. 3. The Breslow thickness had a significant positive correlation with the individual grade of antibody against Melan-A. CONCLUSION: In combination with the antibody against S100 protein and HMB-45, the newly developed antibodies against Melan-A and tyrosinase may be useful in the diagnosis of malignant melanoma.
